Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $10.9552W HIGH $33.78
Volume
322.05 K
Value Traded
22.35 M
Short % Float
16.01%
Days to Cover
3.1
-3.95%Week
-20.44%1 Month
+60.08%3 Month
+94.82%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.80 B
EPS (TTM)
-0.73
P/E Ratio
-
Ent. Value
1.38 B
Total Shares
74.81 M
Float Shares
63.30 M
Insiders
15.38%
Institutions
84.77%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
SDGR Catalyst Timeline
Dated clinical, regulatory and corporate events for Schrodinger, Inc. Common Stock
Catalyst Timeline
Dated clinical, regulatory & corporate events for Schrodinger, Inc. Common Stock
168Total events
2Upcoming
44Tier-1 (high impact)
2020 to 2028Coverage
Upcoming catalysts 2
Event history 50
▲PublicationPresentation
Nature publication of lithium-ion battery electrolyte research using Schrödinger's ML force field platform
◆Timing GuidanceBunsenPresentation
Bunsen agentic AI co-scientist early-access release planned for summer 2026
▲Oral PresentationSGR-3515Presentation
Preliminary Phase 1 data for SGR-3515 presented at AACR 2026
solid tumorssource ↗
●PublicationPresentation
Publication of SARM1 inhibitors discovery with Bristol Myers Squibb
neurodegenerative diseasessource ↗
▲Topline ReadoutaleniglipronClinical Data
Structure Therapeutics announced positive Phase 2 topline results for aleniglipron
obesitysource ↗
●PublicationPresentation
Publication of simulation method for antibody viscosity prediction with Lilly
▲Partnership / LicenseCorporate
Strategic agreement with Manas AI granting access to computational platform
▲Partnership / LicenseCorporate
Schrödinger partners with Lilly to make TuneLab platform available in LiveDesign
◆Topline ReadoutSGR-3515Clinical Data
Initial clinical data for SGR-3515 expected in first half of 2026
advanced solid tumorssource ↗
◆Poster PresentationSGR-1505Presentation
Poster presentation of SGR-1505 data at ASH 2025
relapsed/refractory B-cell malignancies after BTKi or BTKi+BCL2isource ↗
▲Oral PresentationSGR-1505Presentation
SGR-1505 data presented at ASH Annual Meeting
relapsed/refractory B-cell malignancies, Waldenström macroglobulinemiasource ↗
●Quarterly UpdateCorporate
Updated 2025 full-year guidance: software revenue growth 8%-13%, drug discovery revenue $49M-$52M, software gross margin 73%-75%
◆Topline ReadoutSGR-2921Clinical Data
Initial clinical data for SGR-2921 expected
acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)source ↗
◆Topline ReadoutSGR-3515Clinical Data
Initial clinical data for SGR-3515 expected
advanced solid tumorssource ↗
▲Orphan Drug DesignationSGR-1505Designation
FDA granted Orphan Drug Designation for SGR-1505 in Waldenström macroglobulinemia
Waldenström macroglobulinemiasource ↗
▲Preclinical PoCSGR-5573Preclinical
Initial preclinical data for SGR-5573 presented at ESMO Congress
osimertinib-resistant EGFR mutant tumorssource ↗
▲Development Candidate NominationSGR-6016Preclinical
SGR-6016 selected as brain-penetrant NLRP3 inhibitor development candidate
NLRP3-mediated diseasessource ↗
●PublicationSGR-1505Presentation
Publication in Journal of Medicinal Chemistry on discovery of SGR-1505 using physics-based modeling and ML
▲Partnership / LicenseCorporate
Copernic Catalysts announced new ammonia synthesis catalyst; Schrodinger holds equity and collaborates
▲Full ResultszasocitinibClinical Data
Phase 2b results of zasocitinib in psoriatic arthritis published; statistically significant ACR20 at week 12
active psoriatic arthritissource ↗
●PublicationPresentation
Publication in Nature Communications on kinome-wide selectivity using Wee1 inhibitors as case study
▲Partnership / LicenseCorporate
Expanded research collaboration with Ajax Therapeutics adding new JAK target
◆Topline ReadoutSGR-1505Clinical Data
Initial SGR-1505 Phase 1 clinical data to be presented in June
relapsed/refractory B-cell malignanciessource ↗
▲Fast Track DesignationSGR-1505Designation
Fast Track Designation granted for SGR-1505 in Waldenström macroglobulinemia
Waldenström macroglobulinemiasource ↗
●Management ChangeCorporate
Appointment of Richie Jain as CFO, Mannix Aklian as CCO, and expansion of Karen Akinsanya's role
◆Topline ReadoutSGR-2921Clinical Data
Initial SGR-2921 Phase 1 clinical data expected in H2 2025
AML and myelodysplastic syndrome (MDS)source ↗
◆Topline ReadoutSGR-3515Clinical Data
Initial SGR-3515 Phase 1 clinical data expected in H2 2025
advanced solid tumorssource ↗
▲Poster PresentationSGR-3515Presentation
Preclinical data for SGR-3515 presented at AACR 2025
advanced solid tumorssource ↗
▲Poster PresentationSGR-4174Presentation
Initial preclinical data for SGR-4174 presented at AACR 2025
◆Product LaunchPost-Market
Predictive toxicology initiative expected to be available to customers in H2 2025
◆Topline ReadoutSGR-1505Clinical Data
Initial Phase 1 data for SGR-1505 expected in Q2 2025
relapsed/refractory B-cell malignanciessource ↗
▲Platform ValidationPreclinical
Crystal structure prediction method published in Nature Communications
▲Partnership / LicenseCorporate
Expanded research collaboration with Eli Lilly and Company announced
◆FDA Feedback ReceivedSGR-1505FDA Meeting
FDA meeting to discuss recommended Phase 2 dose for SGR-1505
relapsed refractory B-cell malignanciessource ↗
◆Topline ReadoutSGR-1505Clinical Data
Initial Phase 1 data for SGR-1505 expected
relapsed/refractory B-cell malignanciessource ↗
▲Partnership / LicenseCorporate
Expanded research collaboration with Otsuka Pharmaceutical announced
▲Orphan Drug DesignationSGR-2921Designation
FDA granted Orphan Drug Designation for SGR-2921 in AML
acute myeloid leukemia (AML)source ↗
●PublicationPresentation
Schrodinger scientists published paper on FEP accuracy for nucleic acid targets
Past FDA Catalysts and PDUFA Decisions
How SDGR actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-12-31 | SGR-3515 (Wee1/Myt1 inhibitor) | Phase 1 data readout | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every SDGR program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Akinsanya KarenOfficer (See Remarks) | Option | 31,599 101,555 held | $4.34 | 09/17/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in SDGR
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PROSIGHT MANAGEMENT, LP | 1 % (400 %) | 5.80 M | 510.58 K | 1,365.91% ( 475.75 K) |
SDGR Institutional Ownership Trends
SDGR Short Interest
Shares sold short, counted twice a month.
16.01%
Short % of Float
of tradable shares sold short
10.1M
Shares Sold Short
-9.3% vs prior count
3.1 Moderate
Days to Cover
trading days of normal volume to buy every short share back
3.3M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How SDGR ranks across every disease it competes in
Competitive Position is a premium feature
See how SDGR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialSDGR News
-SDGR
Oct 21, 2026▲ +2.6%today
Schrödinger to Announce Third Quarter 2026 Financial Results on November 4
Schrödinger, Inc. (Nasdaq: SDGR) plans to announce its third quarter 2026 financial results on November 4, 2026, after market close. A conference call and webcast will follow at 4:30 p.m. ET, available on the company's website. The event will be archived for 90 days for later access.
Read more →-SDGR
Oct 14, 2026Schrödinger Research Published in Nature Reveals New Insights into Lithium-Ion Battery Chemistry
Schrödinger, Inc. has published research in Nature revealing new insights into lithium-ion battery electrolytes. The study, conducted with Columbia University, found that lithium ions form multi-ion clusters, which significantly impact battery performance. These findings could lead to a shift from empirical design to predictive, computational methods for developing higher-capacity batteries.
Read more →-SDGR
Sep 17, 2026▲ +26.4%on this news
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Schrödinger, Inc. announced the grant of restricted stock units (RSUs) to three new employees as part of its 2021 Inducement Equity Incentive Plan. These grants, totaling 2,243 shares, are intended to incentivize the acceptance of employment and will vest over four years. The decision was approved by the company's compensation committee.
Read more →-SDGR
Sep 9, 2026Schrödinger Announces Licensing and Collaboration Agreement with Tectora Therapeutics, a New Biotechnology Company It Co-founded to Advance Immunology and Inflammation Programs
Schrödinger, Inc. has co-founded Tectora Therapeutics, a new biotech company focused on immunology and inflammation therapies. Tectora has secured $55 million in Series A funding from NEA and RA Capital Management. Schrödinger is contributing two early-stage programs and will collaborate closely with Tectora to advance these initiatives towards clinical development.
Read more →-SDGR
Sep 1, 2026▲ +6.9%on this news
Schrödinger to Present at Morgan Stanley Global Healthcare Conference
Schrödinger, Inc. announced its participation in the Morgan Stanley 24th Annual Global Healthcare Conference. The management will engage in a fireside chat on September 14, 2026, at 1:05 p.m. E.T. The presentation will be available via live webcast and archived for 90 days. Schrödinger's platform is recognized for its role in drug development.
Read more →-SDGR
Aug 5, 2026▲ +8.6%on this news
Schrödinger Reports Second Quarter 2026 Financial Results
Schrödinger, Inc. reported a 27% increase in Annual Contract Value for Q2 2026, reaching $29.6 million. The company launched Bunsen, an AI co-scientist aimed at improving molecular discovery workflows. Despite a decrease in software revenue, total revenue increased by 8% to $58.9 million, and net income rose to $6 million from a loss of $43.2 million in the previous year.
Read more →-SDGR
Jul 27, 2026Schrödinger Introduces Bunsen, an AI Co-Scientist for Molecular Discovery
Schrödinger, Inc. has launched Bunsen, an AI co-scientist designed to enhance molecular discovery. This tool combines AI with physics-based simulations to help researchers streamline their workflows and make more informed decisions. Collaborations with NVIDIA and Google Cloud will provide essential computational support. The early access version is now available, with a full release expected by late 2026.
Read more →-SDGR
Jul 22, 2026Schrödinger to Announce Second Quarter 2026 Financial Results on August 5
Schrödinger, Inc. will announce its second quarter 2026 financial results on August 5, 2026, after market close. A conference call and webcast will follow at 4:30 p.m. ET, accessible via the company's website. The event will be archived for 90 days, ensuring investor access to the information.
Read more →-SDGR
May 5, 2026Schr dinger Reports First Quarter 2026 Financial Results
Schr dinger, Inc. reported a first quarter 2026 financial result with an annual contract value (ACV) of $28 million, demonstrating a 12% growth. The company announced plans to launch Bunsen, an agentic AI co-scientist, aimed at enhancing molecular discovery workflows. Despite some positives, the overall revenue saw a slight decline of 2%, and software revenue dropped by 21% amid the shift to hosted licensing. The acquisition of Ajax Therapeutics by Lilly, in which Schr dinger holds a 6% equity stake, highlights the company's successful partnerships in the biopharmaceutical sector.
Read more →-SDGR
May 4, 2026Schrödinger to Participate in Upcoming May 2026 Investor Conferences
Schrödinger, Inc. (Nasdaq: SDGR) has announced its participation in several investor conferences scheduled for May 2026. The discussions will be accessible via the company's website and archived for 90 days post-event. Schrödinger is known for its advanced computational platform that aids in drug development and materials design.
Read more →-SDGR
May 4, 2026Schrödinger to Participate in Upcoming Investor Conferences
Schrödinger is set to participate in several upcoming investor conferences. The company aims to engage with investors and discuss its latest developments. Specific details about the conferences or topics of discussion were not provided in the article.
Read more →-SDGR
Apr 21, 2026Schrödinger to Announce First Quarter 2026 Financial Results on May 5
Schrödinger, Inc. (Nasdaq: SDGR) will report its first quarter 2026 financial results on May 5, 2026, after market close. A conference call and webcast will follow at 4:30 p.m. ET, accessible via the company's website. This event highlights the company's commitment to investor engagement and transparency.
Read more →-SDGR
Feb 26, 2026▲ +8.1%on this news
Schrödinger Reports Fourth Quarter and Full-Year 2025 Financial Results
Schrödinger, Inc. reported a total revenue of $256 million for 2025, with a notable 23% growth. The company is transitioning to a hosted software model to enhance revenue predictability, despite expecting short-term declines in software revenue. Looking ahead, Schrödinger aims to achieve positive adjusted EBITDA by the end of 2028, supported by its innovative platform and strong customer engagement.
Read more →-SDGR
Feb 18, 2026Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - February 18, 2026
Schrödinger, Inc. has announced the granting of stock options and restricted stock units to newly hired employees as part of its 2021 Inducement Equity Incentive Plan. The grants, totaling 9,600 stock options and 18,250 RSUs, were made to incentivize acceptance of employment. The stock options have a ten-year term and vest over four years, while the RSUs also vest over a similar period.
Read more →-SDGR
Feb 12, 2026▼ -5.6%on this newsshared move
Schrödinger to Announce Fourth Quarter and Full-Year 2025 Financial Results on February 25
Schrödinger, Inc. will announce its fourth quarter and full-year 2025 financial results on February 25, 2026, after market close. A conference call and webcast will follow at 4:30 p.m. ET. The event will be accessible via the company's website and archived for 90 days. Schrödinger focuses on molecular discovery through its advanced computational platform.
Read more →About Schrodinger, Inc. Common Stock
Headquarters1540 BROADWAY, NEW YORK, NY, 10036
BIOPHARMAWATCH ELITE PLUS
Trade the next SDGR catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime